Shares of XenoPort Inc. lost two-thirds of its value Thursday after the firm revealed that its partner GlaxoSmithKline plc had received a complete response letter from the FDA for its application for Horizant (gabapentin enacarbil), also known as GSK1838262 or XP13512, for moderate to severe primary restless legs syndrome (RLS). (BioWorld Today)